After using its Oxford Genome Anatomy Project database to identify 25 potential protein biomarkers for colorectal cancer, Oxford Genome Sciences announced this week that it has partnered with Biosite to develop a diagnostic test for the cancer.

The test will focus initially on detecting colorectal cancer relapse, said Gunars Valkirs, senior vice president in charge of discovery at Biosite. If that test is successful, the companies may then move to apply it as a colorectal screening test for the general population.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.